Ozempic, Mounjaro, and Wegovy have emerged as some of the most discussed weight-loss injections globally, sparking both excitement and skepticism. These drugs have gained popularity, moving from clinical settings to mainstream discussions among celebrities and wellness enthusiasts alike. As the hype around these GLP-1 medications increases, so do several pertinent questions regarding their costs and overall value.
Recent studies affirm their efficacy. The STEP-1 trial, published in 2021 in The New England Journal of Medicine, revealed that adults administered weekly semaglutide, the active compound in Ozempic and Wegovy, lost an impressive 15% of their body weight over 68 weeks-significantly more than those relying solely on lifestyle changes. This study solidified semaglutide’s status as a groundbreaking tool in weight management. A year later, the SURMOUNT-1 trial in 2022 further demonstrated that tirzepatide, the active ingredient in Mounjaro, could lead to average weight reductions of over 20%, a result typically associated with bariatric surgery.
The most recent May 2025 study compared tirzepatide with semaglutide, concluding that tirzepatide not only achieved greater weight loss but also reduced waist size more effectively over a 72-week period. This finding aligns with anecdotal observations from health professionals suggesting that both drugs are effective, yet tirzepatide may have the edge.
Regarding affordability, there’s a stark price disparity between India and the United States. Dr. Rajiv Kovil, a diabetology expert, noted that in the U.S., individuals without insurance may pay close to $900 to $1,300 monthly for these medications. Even with discounts, the costs remain substantial. In contrast, India offers these treatments at relatively lower prices. It’s expected that Ozempic, set to launch in December 2025, will cost around ₹10,000 per month. Wegovy ranges from ₹17,000 to ₹26,000 based on dosage, while Mounjaro is priced between ₹14,000 and ₹27,000 per month. This cost structure means that while these treatments are premium compared to typical medications in India, they remain more accessible compared to U.S. pricing.
Dr. Manjunath Malige from Sakra World Hospital stated that while prices in India are notably lower than in the U.S., they can vary based on dosage and program offerings. The U.S. has started providing direct-to-consumer pricing options around $499 monthly for uninsured patients, making affordability a significant factor for consumers exploring these treatments.
In the U.S., the retail price of these drugs hovers between $900 to $1,300 per month. Despite insurance challenges, new programs are emerging that offer better payment options reflecting the competitive landscape in the GLP-1 market. Meanwhile, for Indian patients seeking to enhance their metabolic health, these drugs are expensive, yet manageable.
However, experts caution against viewing these medications as easy solutions to weight issues. While the scientific support for their efficacy is robust, sustainable weight loss relies heavily on continued usage, medical oversight, and lifestyle changes. The real question surrounding these products is not just whether they work but who can financially sustain their effectiveness over time.
Original Source: https://timesofindia.indiatimes.com/life-style/health-fitness/weight-loss/ozempic-vs-mounjaro-vs-wegovy-prices-in-india-vs-us-and-what-the-research-actually-shows/articleshow/125008302.cms
Category:
Tags:
Publish Date: 2025-11-01 07:57:00
